Director Dealings / Market Share Purchase

RNS Number : 6411C

Oxford Biomedica PLC

23 January 2018

 

Director Dealings / Market Share Purchase

Oxford, UK - 23 January 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the Group, on Monday 22 January 2017 acquired ordinary shares in the Group as set out below under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.

Under the market share purchase agreement, one-third of Dr Tallarigo's fees as Chairman, after tax, are to be used to purchase shares in Oxford BioMedica PLC on a monthly basis at the prevailing market price.

				Interest after purchase
Director / PDMR	Title	Price per share (p)	Number of Ordinary Shares acquired	Number of Ordinary Shares	% of total issued share capital
Dr Lorenzo Tallarigo	Chairman	11.1p	23,941	2,197,028	0.07%

The issued share capital of the Group is 3,107,704,224 ordinary 1p shares.                   

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson,  Chief Executive Officer Stuart Paynter, Chief Financial Officer	Tel: [phone]
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 300 people. Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

DSHUOUKRWKAAURR